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AbstrAct
Abiraterone acetate (ABI) is associated not only with a significant survival 
advantage in both chemotherapy-naive and -treated patients with metastatic 
castration-resistant prostate cancer (mCRPC), but also with a delay in time to 
development of Skeletal Related Events and in radiological skeletal progression. These 
bone benefits may be related to a direct effect on prostate cancer cells in bone or to 
a specific mechanism directed to bone microenvironment. To test this hypothesis we 
designed an in vitro study aimed to evaluate a potential direct effect of ABI on human 
primary osteoclasts/osteoblasts (OCLs/OBLs). We also assessed changes in bone 
turnover markers, serum carboxy-terminal collagen crosslinks (CTX) and alkaline 
phosphatase (ALP), in 49 mCRPC patients treated with ABI. 
Our results showed that non-cytotoxic doses of ABI have a statistically significant 
inhibitory effect on OCL differentiation and activity inducing a down-modulation of 
OCL marker genes TRAP, cathepsin K and metalloproteinase-9. Furthermore ABI 
promoted OBL differentiation and bone matrix deposition up-regulating OBL specific 
genes, ALP and osteocalcin. Finally, we observed a significant decrease of serum CTX 
values and an increase of ALP in ABI-treated patients.
These findings suggest a novel biological mechanism of action of ABI consisting 
in a direct bone anabolic and anti-resorptive activity.
IntroductIon
Several anticancer agents directly influence 
bone remodeling targeting specific bone cells such as 
osteoclasts (OCLs), osteoblasts (OBLs), osteocytes 
and, concomitantly, resulting in bone anabolic and anti-
catabolic therapeutic effects. In this context, a number of 
bone-targeted agents are currently under preclinical and 
clinical investigation such as c-Src inhibitors, integrins 
inhibitors, cathepsin-K inhibitors, endothelin receptor 
antagonists and WNT signaling pathway modulators [1]. 
Abiraterone acetate (ABI) is a selective androgen 
biosynthesis inhibitor that potently and irreversibly blocks 
Cyp17 resulting in virtually undetectable serum and 
intratumoral androgen production in the adrenals, testes 
and prostate cancer cells [2, 3]. In phase III studies in 
metastatic castration-resistant prostate cancer (mCRPC) 
patients, it was demonstrated that ABI treatment is 
associated not only with a significant survival advantage 
in both chemotherapy-naive and chemotherapy-treated 
patients [4-6] but also, in docetaxel treated patients, with 
a better pain control from skeletal metastases, a delay in 
time to development SREs and in radiological skeletal 
progression. More specifically, 25% of patients developed 
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a skeletal event in 9.9 months when treated with ABI and 
4.9 months with placebo and time to first SRE was 25.0 
months with ABI compared to 20.3 months with placebo 
[4, 5]. These ABI effects on metastatic bone disease may 
be secondary to a systemic control of the disease due to a 
direct antitumor effect that, in turns, leads to a decrease of 
cancer cells/OCLs/OBLs vicious circle or, alternatively, 
to a specific action directed to bone microenvironment. 
To test this second hypothesis we have designed a 
translational study aimed to investigate a potential bone 
direct effect of ABI in an in vitro model of human primary 
OCLs/OBLs and in a prospective cohort of castration 
resistant prostate cancer patients in which bone turnover 
markers were assessed during ABI treatment. 
results
cyp17a1 and androgen receptor expression 
during osteoclast and osteoblast differentiation
Cyp17a1 expression was evaluated at different 
stages of osteoclast/osteoblast differentiation by real-time 
PCR. Osteoclast mRNA levels were assessed at three 
different time-points during the differentiation protocol 
[day 0 (monocyte), day 6 (pre-osteoclast), day 12 (mature 
osteoclast)] as well as its expression in the osteoblasts 
was evaluated at day 0 (mesenchymal cells), day 14 (pre-
osteoblast) and day 21 (mature osteoblast). Cyp17A1 
was expressed during all phases of osteoclast/osteoblast 
maturation with a significant increase of mRNA levels at 
early stage of osteoclast differentiation (monocytes vs pre-
OCL p < 0.0001; monocytes vs OCL p < 0.0001) (Fig. S1). 
Conversely Cyp17a1 mRNA levels remained unchanged 
during the osteoblast maturation process (Fig. S1). 
During OCLs/OBLs differentiation Androgen Receptor 
(AR) expression levels were also assessed because it was 
shown by others a direct activity of steroids on bone cells 
[7-12]. AR was expressed at different stages of osteoclast 
differentiation with a significant decrease in the levels of 
transcripts in the mature osteoclasts (monocytes vs OCL 
p < 0.001). Similarly to what observed for Cyp17a1, AR 
mRNA levels were stable during all the phases of OBLs 
differentiation (Fig. S1).
effect of AbI on primary osteoclast differentiation 
and activity in presence or absence of steroids
ABI was administered to primary cells at two 
different concentrations, 5μM and 10μM similarly to other 
preclinical studies that tested 10μM as maximum dose 
in in vitro assays [13-15]. Both doses did not impact on 
Figure 1: effect of abiraterone treatment on primary osteoclast. TRAP and Osteoassay in treated and untreated osteoclasts 
(DMSO) in presence (A) and absence (b) of steroids. * (P < 0.05) ** (P < 0.001) *** (P < 0.0001) **** (P < 0.00001).
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osteoclast viability excluding a possible cytotoxic effect 
(Fig. S3). ABI was added to osteoclast cell cultures every 
3 days and osteoclast differentiation was evaluated at the 
end of the differentiation protocol (day 12) by functional 
TRAP assay. ABI treatment had a statistically significant 
inhibitory effect on osteoclast maturation reducing 
the number of mature TRAP+ osteoclasts compared 
with control (DMSO) (DMSO vs ABI 5 μM p < 0.05; 
DMSO vs ABI 10 μM p < 0.001; ABI 5 μM vs ABI 10 
μM p = 0.032) (fig.1A). The effect of ABI treatment on 
osteoclastic activity was tested by seeding monocytes on 
wells coated with inorganic calcium phosphate to mimic 
bone matrix and evaluating the reabsorbed areas (pits) 
produced by osteoclasts at the end of the differentiation 
protocol. ABI significantly inhibited bone resorption 
interfering with osteoclast function (DMSO vs ABI 5 μM 
p < 0.0001; DMSO vs ABI 10 μM p < 0.0001; ABI 5 μM 
vs ABI 10 μM p = 0.020) (fig.1A). Moreover, the effect 
of ABI on osteoclast differentiation and activity was also 
assessed using a charcoal-treated serum to deplete the 
steroid content in the culture medium. In this deprivation 
status the rate of mature osteoclasts significantly increased 
as well as the ability of these cells to reabsorb bone matrix 
(p < 0.001) (Fig. S2). In such deprivation model, TRAP 
and resorption assay confirmed the anti-resorptive action 
of ABI suggesting an androgen-independent inhibitory 
mechanism (Fig. 1B). 
effect of AbI on primary osteoblast differentiation 
and activity in presence or absence of steroids
The effect of ABI on osteoblastic differentiation has 
been evaluated in both presence and absence of steroids 
using ALP assay that allows identifying the expression 
of ALP, the main enzyme marker for osteoblasts. 
Following ABI treatment osteoblast cultured in steroid-
containing medium showed a significant increase in the 
ALP positivity (DMSO vs ABI 5 μM p = 0.035; DMSO 
vs ABI 10 μM p = 0.30) (Fig. 2A). Osteoblast ability to 
produce bone matrix was analyzed only in presence of 
androgen since steroid deprivation made cells unable 
to induce calcium phosphate deposits. ABI increased 
significantly bone matrix deposition stained by Alizarin 
red assay (DMSO vs ABI 5 μM p = 0.026; DMSO vs ABI 
10 μM p = 0.014) (Fig. 2A). These data demonstrated 
that, unlike osteoclasts, osteoblasts require a source of 
steroids to reach the complete differentiation, although 
ABI treatment results in a partial differentiation rescue in 
the steroid- depleted condition suggesting an androgen-
independent anabolic effect of ABI. Indeed following 
ABI administration the percentage of ALP+ osteoblasts 
was significantly increased compared to control (DMSO 
vs ABI 5 μM p = 0.018; DMSO vs ABI 10 μM p = 0.020) 
as shown in Fig. 2B.
effect of AbI on osteoclast/osteoblast markers
Compared to baseline values, ABI significantly 
down-modulated osteoclast markers such as TRAP (p 
< 0.001), cathepsin-K (P < 0.001), MMP-9 (P = 0.015) 
and up-regulated the expression of osteoblast’ ALP (p = 
0.015) and osteocalcin (p = 0.034) genes both in presence 
and absence of steroids (Fig. 3A and 3B). The reduction 
of cathepsin-K levels and the increase of osteocalcin 
expression were confirmed by Western Blot analyses (Fig. 
3A and 3B).
effect of AbI on bone turnover markers in 
prostate cancer patients
Forty-nine consecutive patients were recruited. 
Eighteen of them have the last follow up visit 10 months 
after the end of treatment. Patients’ characteristics are 
reported in Table 1. Median age was 67 years. Sixteen 
of them had Gleason Score (GS)=7, six GS<7, twenty-
three GS>7. 16 patients had bone metastases, 18 patients 
bone and lymph nodes metastases, 9 patients lymph nodes 
metastases, 3 patients bone and visceral metastases, 1 
patient visceral metastases, 1 patient bone metastases and 
local recurrence, 1 patient bone, lymph nodes and visceral 
metastases. Twenty patients started zoledronic acid at least 
three months before beginning ABI treatment. The median 
number of zoledronic acid doses before ABI therapy was 
12. 
A significant decrease in CTX values was observed: 
at baseline the median value was 0.86 ng/mL (95% 
confidence interval [CI]: 0.84-1.25), and at three, six and 
nine months it was 0.78 ng/mL (95%CI: 0.67-1.01) (p = 
0.077), 0.61 ng/mL (95%CI: 0.73-1.19) (p = 0.027) and 
0.66 ng/mL (95%CI: 0.38-0.71) (p = 0.006), respectively 
(Table 2, Fig. 4). Compared to median value at baseline 
table 1: Patients characteristics.
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Figure 2: effect of abiraterone treatment on primary osteoblast. ALP and Alizarin Red assay in treated and untreated osteoclasts 
(DMSO) in presence (A) and absence (b) of steroids. * (P < 0.05).
Figure 3: Gene and protein expression analyses. (A). TRAP, CATH-K and MMP-9 mRNA levels (Real Time PCR) and CATH-K 
protein levels (Western Blot) in treated and untreated osteoclasts (DMSO) cultured with steroids. (b). ALP, OCN, and RUNX2 mRNA 
levels (Real Time PCR) and OCN protein levels (Western Blot) in treated and untreated osteoclasts (DMSO) cultured with steroids. * (P 
< 0.05) ** (P < 0.001).
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Figure 4: comparison between ctX at baseline and after three, six and nine months.
Figure 5: comparison between AlP at baseline and after three, six and nine months.
table 2: difference in median level of bone resorption and formation markers.
ctX baseline  ng/ml three months ng/ml six monthsng/ml
nine months
ng/ml
Median, 95% IC 0.86, (0.84-1.25) 0.78, ( 0.67-1.01) 0.61, (0.73-1.19) 0.66, (0.38-0.71)
p (compare to 
baseline) p=0.077 p=0.027 p=0.006
ALP Baseline U/L Three months U/L Six months U/L
Nine months 
U/L
Median, 95% IC 123, (126-261) 143, (255-382) 126, (200-327) 190, (172-344)
p (compare to 
baseline) p=0.01 p=0.62 p=0.28
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a CTX decrease by 9.3%, 29% and 23% was observed at 
three, six and nine months, respectively. 
ALP did not show a significant increase, median 
123 U/L (95%CI: 126-261) and 190 U/L (95%CI 172-
344) at baseline and nine months (p = 0.28), respectively. 
However, the comparison between ALP at baseline and 
after 3 months showed a significant increase (p = 0.010) 
(Table 2, Fig. 5). Compared to median value at baseline an 
ALP increase by 16.3%, 2.4% and 54.5% was observed at 
three, six and nine months, respectively. 
dIscussIon
The results of the present study demonstrate for the 
first time a direct bone anabolic and an anti-resorptive 
effect of ABI both in vitro and in castration resistant 
prostate cancer patients. Indeed, ABI is able to specifically 
modulate osteoclast/osteoblast differentiation without 
generating any cytotoxic and/or proliferative effect at the 
administrated doses. Moreover, our findings show that 
ABI regulates gene expression in bone cells modulating 
mRNA levels of key osteoclastic/osteoblastic genes. 
Intriguingly, we observed that anabolic and anti-resorptive 
effects are produced both in presence and absence of 
steroids suggesting a non-canonical mechanism of action 
that seems to be, at least in part, androgen-independent. 
Recently Bruno et al. reported about an alternative 
mechanism analyzing the effect of ABI and other specifc 
CyP17 inhibitors in an androgen-independent prostate 
cancer cell line (PC-3) [16]. The treatment induced a 
rapid release of calcium from the endoplasmic reticulum 
(ER) resulting in disruption of calcium homeostasis. 
This, in turns, led to the ER stress response (ERSR), also 
known as “unfolded protein response” (UPR) through the 
phosphorylation of the translation elongation factor eIF2α 
and the up-regulation of stress response genes, triggering 
cell cycle arrest. Moreover, recent evidences showed 
that eIF2α phosphorylation promotes the activation of 
ATF4, a key osteoblastic transcriptional factor, leading to 
osteocalcin up-regulation and down-modulation of a key 
pro-osteoclastic factor, NFATc1, resulting in bone matrix 
production [17]. Taken together these data suggest a novel 
potential molecular mechanism of ABI that, acting through 
eIF2α phosphorylation, may promote osteoblastogenesis 
and inhibit osteoclast-dependent bone resorption. These 
promising in vitro results provided a strong rationale to 
design a translational study to investigate the potential 
modulation of serum bone turnover markers by ABI 
treatment in a cohort of 49 metastatic castration resistant 
prostate cancer patients (mCRPC). Our findings showed 
that in these patients ABI significantly inhibited bone 
resorption as documented by a decrease of serum CTX 
values and enhanced new bone formation as shown by an 
increase of ALP in agreement with in vitro data.
Overall, our pre-clinical and clinical data provide a 
biological rationale for the high efficacy of ABI treatment 
in improving multiple skeletal disease specific clinical 
endpoints as recently documented in the context of phase 
III clinical trials. Molecules that simultaneous target 
prostate cancer cells and bone microenvironment could 
significantly influence future therapeutic approaches in 
order to achieve a better disease control and management 
of prostate cancer bone metastases. If further prospective 
confirmation will be obtained these pivotal results justify 
a potential synergistic effect of ABI with bone-targeted 
therapies (bisphosphonates and denosumab).
In conclusion, these findings represent the first 
evidence of a novel mechanism of ABI directed on bone 
microenvironment together with the known antitumoral 
effect on CRPC cells and pave the way to new treatment 
scenarios for bone metastatic prostate cancer. 
MAterIAls And MetHods
Primary cell culture
Human peripheral blood mononuclear cells 
(PBMCs) were isolated from buffy-coat of 10 male healthy 
donors by Lympholyte®-H density gradient (Cedarlane 
Laboratories) and monocytes were sorted using beads 
conjugated anti-human CD14 (Miltenyi Biotech) and 
cultured for 12 days in RPMI culture medium (Euroclone) 
supplemented with 10% fetal bovine serum (Hyclone, 
Thermo Scientific) or 10% charcoal stripped serum 
(Sigma-Aldrich), 100 units/ml penicillin, 100 mg/ml 
streptomycin (Euroclone), 2 mM L-glutamine (Euroclone), 
25 ng/mL macrophage-colony stimulating factor (M-CSF) 
and 50 ng/mL receptor activator of nuclear factor kappa-B 
ligand (RANKL) (R&D Systems) to differentiate them 
into osteoclast. During the differentiation protocol (from 
day 1 to 12), cells were treated with 5-10 µM of ABI 
acetate (Selleckem) or vehicle as control.
Primary human osteoblasts were differentiated from 
human mesenchymal stem cells (hMSCs) gently gifted by 
Cell Culture Laboratory, Department of Biomedicine and 
Prevention of the University Tor Vergata, Rome. HMSCs 
were cultured for 21 days in alpha MEM (Euroclone) 
supplemented with 15% fetal bovine serum or 15% 
charcoal stripped serum, 100 units/ml penicillin, 100 
mg/ml streptomycin, 2 mM L-glutamine, 10 mM beta-
glycerophosphate (Sigma-Aldrich), 50 µM ascorbic acid 
(Sigma-Aldrich) and 100 nM dexamethasone (Sigma-
Aldrich). During the differentiation protocol (from day 1 
to 21), cells were treated with 5-10 µM of ABI acetate or 
vehicle as control. 
All culture media, growth factors, cytokine and ABI 
acetate were replaced every 3-4 days [18-19].
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osteoclast functional assays
At the end of the differentiation protocol (day 12) 
culture medium was removed and cells were fixed with 
4% formaldehyde for 5 minute and stained with leukocyte 
acid phosphatase (TRAP) kit (Sigma-Aldrich) according 
to manufacturer’s instructions. Stained positive cells (>3 
nuclei) were then counted [20]. 
Osteoclasts activity was assessed culturing cells 
on plates coated with a synthetic inorganic bone mimetic 
matrix (Osteoassay, Corning). At day 12 the culture 
medium was removed and plates were filled with sodium 
hypochlorite solution to evaluate the ability of mature 
osteoclasts to reabsorb this substrate; pits produced by 
osteoclasts re-absorptive activity were quantified by 
ImageJ software.
osteoblast functional assays
On day 21 cells were fixed with 4% formaldehyde 
for 5 minute and stained with alkaline phosphatase (ALP) 
kit (Sigma-Aldrich) according to the manufacturer’s 
protocol. ALP positivity was quantified by ImageJ 
software.
In order to detect bone matrix deposition as a 
marker of osteoblastic activity cells were fixed with 
4% formaldehyde for 20 minute and stained with 
alizarin red for 1 hour at room temperature. Alizarin red 
fluorescence was detected at 470 nm and quantified by 
spectrofluorimeter (Tecan Infinite M200Pro) [19].
Mtt assay
Cell viability was evaluated by cell growth 
determination kit, MTT-based assay (Sigma-Aldrich), 
and performed according to manufacturer’s instructions; 
the optical density (OD) of the colored complex formed 
was read by spectrophotometer with 570 nm wavelength 
and background absorbance at 690 nm wavelength was 
subtracted.
rnA extraction and gene expression analysis
Total RNA was extracted from osteoclast and 
osteoblast cells at the end of the differentiation protocol 
using the Trizol reagent (Invitrogen) according to the 
manufacturer’s instructions. RNA was treated with DNase 
buffer and DNase (DNAse Turbo, Applied Biosystems) to 
avoid genomic DNA contamination. cDNA was produced 
using the High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems) according to the manufacturer’s 
instructions. mRNA levels were measured by quantitative 
real-time polymerase chain reaction (qRT-PCR) using 
TaqMan Gene Expression Assays in 7900HT Real-
Time PCR System (Applied Biosystems). Tartrate 
resistant acid phosphatase (TRAP) (Hs00356261_m1), 
cathepsin-K (Hs00166156_m1), metalloproteinase-9 
(Hs00234579_m1), alkaline phosphatase (ALP) 
(Hs01029144_m1), osteocalcin (Hs00234160_m1) 
and runt-related transcription factor 2 (RUNX2) 
(Hs00231692_m1) expression levels were normalized to 
the endogenous housekeeping gene glucuronidase beta 
(GUSb) (Hs99999908_m1) in both untreated and treated 
samples using the ΔCT calculation. Subsequently relative 
expression levels in treated samples were normalized to 
the mRNA levels detected in control samples using the 
ΔΔCT calculation [21].
Protein extraction and western blot analysis
Cell lysates was obtained using 
radioimmunoprecipitation assay buffer (RIPA buffer) 
(Sigma-Aldrich) and quantified using DC protein assay 
kit (Bio-Rad). Twenty mg of the total protein extract from 
each sample was loaded on 8%/15% SDS-PAGE gels, 
transferred onto nitrocellulose membranes through Trans-
Blot Turbo Transfer System (Bio-Rad) and incubated in 
a blocking buffer (TBST 1X with 5% non-fat dry milk) 
for one hour. Mouse monoclonal anti-human Cat-K (Santa 
Cruz Biotechnologies), rabbit polyclonal anti-human OCN 
(Santa Cruz Biotechnologies) and mouse anti-human 
Actin-β (Sigma-Aldrich) were incubated for 2 hours at 
room temperature. Anti-rabbit/mouse HRT-coniugated 
antibody (Abcam) was used and the chemiluminescence 
signal detected using ChemiDoc (Bio-Rad) and Quantity 
One software (Bio-Rad) to quantify the bands’ signal 
intensity. 
Patients
Patients with metastatic castration resistant prostate 
cancer (mCRPC) with or without bone metastases in 
clinical progression following treatment with docetaxel 
and enrolled in the ABI acetate expanded access program 
at the Division of Medical Oncology-S. Luigi Hospital, 
Orbassano were prospectively assessed. ABI acetate was 
administered at the dose of 1.000 mg daily with prednisone 
5 mg twice a day in combination with luteinizing 
hormone releasing hormone analogue until radiological or 
serological progression. A subgroup of patients was also 
treated with zoledronic acid at standard unchanged doses 
in the last three months before starting ABI. All patients 
were evaluated for bone formation and resorption. 
Serum alkaline phosphatase (ALP) as a marker 
of osteoblast activity and serum c-telopetide of type-I 
collagen (CTX) as a marker of bone resorption were 
assessed every 3 months at a centralized laboratory at 
San Luigi Hospital Orbassano. Total ALP was evaluated 
by standard automated analytical procedures (Architect, 
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Abbott) and normal levels ranged between 30 and 120 
U/L. Serum CTX level was measured using a commercial 
ELISA kit (IDS-iSYS CTX-I, Immunodiagnostic Systems 
Ltd). Normal values, minimum detectable concentrations, 
intra- and inter assay coefficients of variation of CTX were 
as follows: 0.12-0.75 ng/mL, 0.023 ng/mL, 3.2 and 6.3 %.
statistical analysis
In vitro data were analyzed using the Student t test 
and One-Way ANOVA test followed by Tukey’s multiple 
comparison tests. The graphics processing and statistical 
tests were performed using the program GraphPad Prism 
(San Diego, CA).
For marker analyses Wilcoxon’s matched pairs sign-
rank test was used to compare pair data at baseline and 
after 3, 6 and 9 months of treatment. All p-values reported 
were two-sided; p-values <0.05 were chosen for statistical 
significance. Statistical computation was performed using 
the SPSS for Windows software package.
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